3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
164
Prednisone
130
enzalutamide
127
Docetaxel
123
Abiraterone Acetate
95
Nivolumab
93
Gemcitabine
71
Sunitinib
67
abiraterone
51
atezolizumab
50
Leuprolide
49
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
48
Cisplatin
48
radium Ra 223 dichloride
39
darolutamide
39
Sorafenib
39
apalutamide
38
Ipilimumab
38
Carboplatin
37
Prednisolone
33
Everolimus
33
Axitinib
32
cabozantinib
31
avelumab
31
pazopanib
30
Bevacizumab
30
Paclitaxel
29
enfortumab vedotin
28
bicalutamide
28
Cyclophosphamide
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
cabiralizumab
×
Genitourinary
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts